She was also areflexic. Electromyography confirmed severe sensorimotor peripheral neuropathy. Right sural nerve and rectal biopsies confirmed amyloidosis on Congo red staining. Laboratory studies ...

In these patients, hereditary ATTR amyloidosis usually presents as a peripheral sensory, motor and autonomic neuropathy starting in a person’s 20s or 30s. In the United States, the most common ...

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in ...

How do you decide whether to continue or discontinue treatment with an amyloid-targeting therapy?

leading to amyloid deposits in the heart, gastrointestinal tract, and peripheral nerves. Life expectancy is a median of 4.7 years after hATTR with neuropathy is diagnosed, less in hATTR patients ...

New probes detect protein aggregates in salivary gland samples from patients with familial amyloid neuropathy (arrows). Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of ...

People with transthyretin cardiac amyloidosis (ATTR-CA ... and autonomic and peripheral neuropathy. "Recognizing these associated features could help clinicians identify patients who may benefit ...

How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the ...

The following is a summary of “Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages,” published in the April 2025 issue of Journal of Neurology by ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

ATTR amyloidosis is an aggressive ... which showed that the drug achieved a 2.2-point decrease (improvement) in neuropathy scores, versus a 14.8-point increase for placebo.